Bactiguard Holding AB (publ) (BACTI-B.ST)
SEK 30.6
(5.15%)
SEK 30.6
(5.15%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -138.38 Million SEK | -161.71% |
| 2022 | -52.87 Million SEK | 10.03% |
| 2021 | -58.77 Million SEK | -53.1% |
| 2020 | -38.38 Million SEK | -336.15% |
| 2019 | 16.25 Million SEK | 208.87% |
| 2018 | -14.93 Million SEK | -359.27% |
| 2017 | -3.25 Million SEK | 87.89% |
| 2016 | -26.85 Million SEK | -1.32% |
| 2015 | -26.5 Million SEK | 72.12% |
| 2014 | -95.04 Million SEK | -2689.61% |
| 2013 | -3.4 Million SEK | 91.12% |
| 2012 | -38.35 Million SEK | -150.63% |
| 2011 | -15.3 Million SEK | 38.16% |
| 2010 | -24.75 Million SEK | -422.73% |
| 2009 | 7.66 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -4.67 Million SEK | 67.36% |
| 2024 Q1 | -9.9 Million SEK | 63.62% |
| 2024 Q2 | -14.31 Million SEK | -44.61% |
| 2023 Q4 | -27.21 Million SEK | -10.63% |
| 2023 FY | -138.38 Million SEK | -161.71% |
| 2023 Q1 | -22.09 Million SEK | -55.87% |
| 2023 Q2 | -64.46 Million SEK | -191.71% |
| 2023 Q3 | -24.6 Million SEK | 61.84% |
| 2022 Q3 | -8.54 Million SEK | 37.51% |
| 2022 Q4 | -14.17 Million SEK | -65.9% |
| 2022 FY | -52.87 Million SEK | 10.03% |
| 2022 Q1 | -16.47 Million SEK | 35.14% |
| 2022 Q2 | -13.67 Million SEK | 17.0% |
| 2021 Q1 | -10.54 Million SEK | 2.6% |
| 2021 Q3 | -10.79 Million SEK | 10.29% |
| 2021 Q4 | -25.4 Million SEK | -135.38% |
| 2021 FY | -58.77 Million SEK | -53.1% |
| 2021 Q2 | -12.03 Million SEK | -14.09% |
| 2020 Q2 | -272 Thousand SEK | -116.76% |
| 2020 Q1 | 1.62 Million SEK | 4.11% |
| 2020 FY | -38.38 Million SEK | -336.15% |
| 2020 Q3 | -16.11 Million SEK | -5824.26% |
| 2020 Q4 | -10.82 Million SEK | 32.82% |
| 2019 FY | 16.25 Million SEK | 208.87% |
| 2019 Q4 | 1.55 Million SEK | -93.43% |
| 2019 Q3 | 23.71 Million SEK | 521.47% |
| 2019 Q2 | -5.62 Million SEK | -64.39% |
| 2019 Q1 | -3.42 Million SEK | 38.07% |
| 2018 Q3 | -526 Thousand SEK | 41.75% |
| 2018 Q4 | -5.52 Million SEK | -950.76% |
| 2018 FY | -14.93 Million SEK | -359.27% |
| 2018 Q1 | -7.97 Million SEK | -767.79% |
| 2018 Q2 | -903 Thousand SEK | 88.68% |
| 2017 Q4 | -919 Thousand SEK | -109.82% |
| 2017 Q3 | -438 Thousand SEK | 92.67% |
| 2017 FY | -3.25 Million SEK | 87.89% |
| 2017 Q2 | -5.97 Million SEK | -246.4% |
| 2017 Q1 | 4.08 Million SEK | 155.1% |
| 2016 Q3 | -526 Thousand SEK | 93.17% |
| 2016 Q4 | -7.4 Million SEK | -1308.56% |
| 2016 Q1 | -11.21 Million SEK | -213.56% |
| 2016 FY | -26.85 Million SEK | -1.32% |
| 2016 Q2 | -7.69 Million SEK | 31.35% |
| 2015 Q3 | 6.05 Million SEK | 151.22% |
| 2015 Q1 | -30.61 Million SEK | -95.58% |
| 2015 FY | -26.5 Million SEK | 72.12% |
| 2015 Q2 | -11.81 Million SEK | 61.4% |
| 2015 Q4 | 9.87 Million SEK | 63.16% |
| 2014 Q2 | -44.08 Million SEK | -125.03% |
| 2014 Q4 | -15.65 Million SEK | 0.42% |
| 2014 FY | -95.04 Million SEK | -2689.61% |
| 2014 Q3 | -15.71 Million SEK | 64.34% |
| 2014 Q1 | -19.59 Million SEK | -203.54% |
| 2013 Q3 | -5.13 Million SEK | 62.84% |
| 2013 Q4 | 18.92 Million SEK | 468.33% |
| 2013 Q1 | -3.36 Million SEK | -278.24% |
| 2013 Q2 | -13.82 Million SEK | -310.54% |
| 2013 FY | -3.4 Million SEK | 91.12% |
| 2012 Q2 | -25.92 Million SEK | 0.0% |
| 2012 FY | -38.35 Million SEK | -150.63% |
| 2012 Q4 | 1.88 Million SEK | 111.4% |
| 2012 Q3 | -16.56 Million SEK | 36.08% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | -15.3 Million SEK | 38.16% |
| 2010 FY | -24.75 Million SEK | -422.73% |
| 2009 FY | 7.66 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | -77.78% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 233.702% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 233.702% |
| Arcoma AB | 2.56 Million SEK | 5497.114% |
| BICO Group AB (publ) | -835.7 Million SEK | 83.441% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 654.038% |
| CellaVision AB (publ) | 130.3 Million SEK | 206.195% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | -73.428% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | -374.127% |
| C-Rad AB (publ) | 35.52 Million SEK | 489.49% |
| Duearity AB (publ) | -26.19 Million SEK | -428.377% |
| Dignitana AB (publ) | -17.36 Million SEK | -696.994% |
| Episurf Medical AB (publ) | -94.8 Million SEK | -45.973% |
| Getinge AB (publ) | 2.41 Billion SEK | 105.737% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | -103.571% |
| Iconovo AB (publ) | -45.89 Million SEK | -201.526% |
| Integrum AB (publ) | 4.03 Million SEK | 3531.686% |
| Luxbright AB (publ) | -25.37 Million SEK | -445.345% |
| Mentice AB (publ) | -2.81 Million SEK | -4812.389% |
| OssDsign AB (publ) | -130.49 Million SEK | -6.046% |
| Paxman AB (publ) | 8.33 Million SEK | 1761.248% |
| Promimic AB (publ) | -9.22 Million SEK | -1400.564% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 13.487% |
| SciBase Holding AB (publ) | -55.58 Million SEK | -148.956% |
| ScandiDos AB (publ) | -14.64 Million SEK | -844.781% |
| Sectra AB (publ) | 428.38 Million SEK | 132.303% |
| Sedana Medical AB (publ) | -59.61 Million SEK | -132.138% |
| Senzime AB (publ) | -134.14 Million SEK | -3.155% |
| SpectraCure AB (publ) | -20.44 Million SEK | -576.983% |
| Stille AB | 26.64 Million SEK | 619.335% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 96.407% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 250.71% |